Can Wegovy Make You Blind? What the Evidence Actually Shows

You read a headline about Wegovy and blindness, here is what that story was actually about

The concern centres on a 2024 observational study published in JAMA Ophthalmology, which found that people taking semaglutide (the active ingredient in Wegovy) were diagnosed with NAION at a higher rate than people taking other medicines for weight management or type 2 diabetes. NAION is a sudden reduction in blood flow to the optic nerve, it can cause permanent vision loss, usually in one eye, and it tends to appear without pain.

Observational data like this cannot prove that semaglutide causes NAION. It shows an association, which is different. The study population had characteristics (obesity, cardiovascular risk factors, diabetes) that themselves raise the background risk of NAION, and unpicking cause from correlation takes more work. Regulators, including the European Medicines Agency and the MHRA, launched reviews in late 2024 and into 2025 to examine all available safety data. As of mid-2026, NAION appears in the Wegovy product information as a potential risk under active monitoring, but regulators have not concluded that the medicine causes the condition. You can read the NHS's patient-level information on semaglutide, including its known and monitored side effects, on the NHS medicines page for semaglutide.

The honest answer to the question of whether Wegovy can make you go blind is: it almost certainly does not in the vast majority of users, but a specific rare eye event has been flagged and is being watched closely, and that means the conversation between you and your prescriber matters.

What the known risks to vision actually are on Wegovy

Setting NAION aside, there are two other contexts where vision and semaglutide intersect. First, people with type 2 diabetes who start any GLP-1 medicine and achieve rapid blood-sugar improvement can sometimes experience a temporary worsening of diabetic retinopathy, the eye damage caused by long-term high blood sugar. This is not unique to Wegovy and is generally managed through regular eye screening, which should already be in place for anyone with diabetes. Second, the common side effects of Wegovy are gastrointestinal: nausea, vomiting, diarrhoea and fatigue tend to be what people experience in the early weeks, not eye problems. Those effects typically ease after the first dose or two.

Across the STEP clinical trial programme, which enrolled thousands of adults with obesity and produced the evidence behind the UK licence, serious eye events were not among the primary safety findings. The STEP 1 trial (the pivotal 68-week study that underpins much of what we know about semaglutide 2.4mg) reported its full safety profile in the New England Journal of Medicine, and NAION was not a pre-specified concern at the time. The 2024 observational finding emerged from post-market surveillance, exactly the kind of monitoring that regulators require for Black Triangle medicines like Wegovy.

If you are thinking about Wegovy for weight management and have a history of NAION, glaucoma or other optic nerve conditions, your prescriber needs to know before a prescription is issued.

What to do if your vision changes while you are on Wegovy

Sudden painless vision loss in one eye, blurred vision that comes on quickly, or anything that feels like a curtain drawing across part of your visual field, these are emergency symptoms. Call 999 or go to A&E the same day. Do not wait until your next clinic appointment, and do not wait to find out whether it is definitely related to Wegovy and the vision risks that have been raised about it. Time matters with optic nerve events.

Milder changes (gradual blurring, floaters that are new or increasing) should be reported to your prescriber and your optician promptly, not urgently-emergency, but not left for weeks either. At nume, our clinical team is reachable seven days a week through aftercare, so you do not have to wait until Monday after a bank holiday if something feels off. That kind of access matters most on a medicine that is still accumulating real-world safety data.

The MHRA operates the Yellow Card scheme for reporting suspected side effects on any medicine. If you experience a new eye symptom on semaglutide and your prescriber is aware, you or they can also report it at yellowcard.mhra.gov.uk, these reports feed directly into ongoing safety monitoring and help regulators build a clearer picture faster.

Putting the risk in context before you decide

NAION affects roughly two to ten people per 100,000 in the general population each year, it is genuinely rare. Even if the association with semaglutide holds up under further scrutiny, we are not talking about a common outcome. Risk always needs context, and the clinical trials that led to Wegovy's UK licence found meaningful, lasting weight loss for many participants: around 15% average body weight reduction over 68 weeks at the 2.4mg maintenance dose in STEP 1. Obesity itself carries serious risks to cardiovascular health, metabolic function and quality of life, and those weigh heavily in the clinical calculation too.

This is precisely why treatment decisions are not made by a form or a checklist alone. A GPhC-registered prescriber reviewing your consultation will consider your eye history, your cardiovascular risk profile, any existing conditions, and what the evidence shows, all of it. If you want to understand how that process works, our guidance on accessing Wegovy through a regulated UK pharmacy walks through what to expect. There is also a broader look at other safety questions patients ask about Wegovy on a separate page. And if you are weighing Wegovy against other options, our overview of what Wegovy is also known as and how it compares to related treatments covers what is licensed for weight management in the UK right now.

If, after reading this, you want to discuss your individual circumstances with a prescriber, start your free consultation with nume and a clinician will review your case the same day.